Quick Answer
Intellia Therapeutics, Inc. reported Total Revenue of $67.67 million for the year ending 2025.
- Intellia Therapeutics, Inc. showed an increase of +16.9% in Total Revenue from 2024 to 2025.
- This data is from Intellia Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2017: $6.22 million | Q2 2017: $5.92 million | Q3 2017: $7.32 million | Q4 2017: $6.67 million | Q1 2018: $7.47 million | Q2 2018: $7.68 million | Q3 2018: $7.41 million | Q4 2018: $7.88 million | Q1 2019: $10.43 million | Q2 2019: $11.12 million | Q3 2019: $10.62 million | Q4 2019: $10.94 million | Q1 2020: $12.92 million | Q2 2020: $16.26 million | Q3 2020: $22.22 million | Q4 2020: $6.60 million | Q1 2021: $6.45 million | Q2 2021: $6.55 million | Q3 2021: $7.20 million | Q1 2022: $11.25 million | Q2 2022: $14.03 million | Q3 2022: $13.27 million | Q1 2023: $12.61 million | Q2 2023: $13.59 million | Q3 2023: $11.99 million | Q1 2024: $28.94 million | Q2 2024: $6.96 million | Q3 2024: $9.11 million | Q1 2025: $16.63 million | Q2 2025: $14.25 million | Q3 2025: $13.78 million.
- Over the full 10 years of available data (2016 to 2025), Intellia Therapeutics, Inc.'s Total Revenue has grown by 310.6%.
- Historical annual values: Fiscal year 2025: $67.67 million | Fiscal year 2024: $57.88 million | Fiscal year 2023: $36.28 million | Fiscal year 2022: $52.12 million | Fiscal year 2021: $33.05 million | Fiscal year 2020: $57.99 million | Fiscal year 2019: $43.10 million | Fiscal year 2018: $30.43 million | Fiscal year 2017: $26.12 million | Fiscal year 2016: $16.48 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: